Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages

  Tyynismaa, Henna ^a   Raivio, Taneli ^c   Hakkarainen, Antti ^b   Ortega Alonso, Alfredo ^b   Lundbom, Nina ^b   Kaprio, Jaakko ^b,d   Rissanen, Aila ^e   Suomalainen, Anu ^a,b,e   Pietiläinen, Kirsi H ^b,e  

^a BIOMEDICUM HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DIZYGOTIC TWINS; FAT CONTENT; HEREDITY; HERITABILITY; HOMEOSTASIS; HUMAN; INTRAABDOMINAL FAT; LIVER FAT; MONOZYGOTIC TWINS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SUBCUTANEOUS FAT;

ABDOMINAL FAT; ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADIPOSITY; ADULT; AREA UNDER CURVE; BODY COMPOSITION; BODY MASS INDEX; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HUMANS; LIFE STYLE; LINEAR MODELS; LIPID METABOLISM; LIVER; MALE; SUBCUTANEOUS FAT; TWINS; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 79951713560     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1326     Document Type: Article

References (20)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB 2005 FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635 (Pubitemid 40814671)
2. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E 2009 Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931-4940
3. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T, Itoh N 2009 Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150: 4625-4633
4. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E 2007 Hepatic fibroblast growth factor 21 is regulated by PPARαand is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437 (Pubitemid 46825495)
5. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA 2007 Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425 (Pubitemid 46825496)
6. Lundåsen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M 2007 PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360:437-440 (Pubitemid 47039157)
7. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M 2008 The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 8:169-174
8. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A 2008 Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253
9. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W 2009 Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151-2156
10. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M 2009 Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71:369-375
11. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F 2009 Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 94:3594-3601
12. Dostálová I, Kaválková P, Haluziková D, Lacinová Z, Mráz M, Papezová H, Haluzik M 2008 Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93:3627-3632
13. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO, Clemenz M, Pfeiffer AF, Kintscher U, Spuler S, Spranger J 2009 Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 58:1532-1538
14. Kaprio J 2006 Twin studies in Finland 2006. Twin Res Hum Genet 9:772-777
15. Pietrobelli A, Formica C, Wang Z, Heymsfield SB 1996 Dual-energy X-ray absorptiometry body composition model: review of physical concepts. Am J Physiol 271:E941-E951
16. Pietiläinen KH, Rissanen A, Kaprio J, Mäkimattila S, Häkkinen AM, Westerbacka J, Sutinen J, Vehkavaara S, Yki-Järvinen H 2005 Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 288:E768-E774 (Pubitemid 40397213)
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
18. Posthuma D, Beem AL, de Geus EJ, van Baal GC, von Hjelmborg JB, Iachine I, Boomsma DI 2003 Theory and practice in quantitative genetics. Twin Res 6:361-376 (Pubitemid 38019774)
19. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W 2010 Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934-940
20. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E 2010 Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456-463